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terrogated and CTC counts ranged from 1 to 8 cells. These ﬁndings are
supported by previous observations that more CTCs were detected in
right atrial blood than in peripheral venous blood in patients with hepa-
tocellular carcinoma (Fang et al., 2014). Similarly, CTCs were found at
higher number localized to the hepatic portosystemic macrocirculation
than in peripheral blood (Jiao et al., 2009).
These results suggest that venous blood might not be the ideal
source of CTCs. Venous blood not only has been ﬁltered through theThe study of circulating tumor cells (CTCs) has been largely
confounded by the low number of these cells in the blood stream
amid billions of other cells. To overcome this challenge numerousmeth-
odologies for CTC isolation have been described. Photoacoustic ﬂow cy-
tometry (Nedosekin et al., 2013), dielectrophoresis array (Maltoni et al.,
2015) and microﬂuidics (Warkiani et al., 2015) are among the most
sophisticated of these methodologies. However, methods based on
immunecapture and immunestaining are still the more frequently uti-
lized, with CellSearch® remaining the most commonly used method
to date and the only US FDA approved (Alix-Panabieres and Pantel,
2014).
Irrespective of the method of isolation and detection used most
studies fail to detect CTCs in the numerous cases. This is particularly un-
expected in studies of cases with metastatic disease, in which patients
with substantial tumor burden have been found with undetectable
CTC levels.
The lack of detection of CTCs is usually attributed to limitations on
the methodologies utilized such as the conditions of collection and
treatment of the samples, the cell size, clustering of CTCs and the high
phenotypic plasticity of cancer cells. One common concern is the lack
of epithelial markers in disseminating carcinoma cells that experienced
epithelial-to-mesenchymal transition (Rao et al., 2005). Moreover, the
low number of CTCs usually detected, 1–10 cells in 7.5 ml of blood, is
susceptible to stochastic distribution in the sampled blood.
The study by Terai and colleagues published in EBioMedicine pro-
vides an alternative explanation to this lack of CTCs (Terai et al.,
2015). The authors compared the number of CTCs in arterial and venous
blood samples from patients with metastatic uveal melanoma. CTCs
were detected in all patients when arterial blood was analyzed
and the number of CTCs ranged from 1 to 168 cells in 7.5 ml of blood,
with 35% of cases presenting more than 10 CTCs. In contrast onlyom.2015.09.019.
. This is an open access article underlung, but also has been carried through the arteries into the tissue cap-
illary bed before being sampled. It is likely that circulation through the
capillary network signiﬁcantly affect the CTCs. First, it is commonly ac-
knowledged that CTCs are larger than most blood cells, less deformable
and frequently travel in clusters (Aceto et al., 2014). However these cells
must transverse through narrow capillaries to reach venous circulation.
For normal blood cells the shear stress is ﬁve times higher in arterioles
and capillaries than in major arteries or veins (Papaioannou and
Stefanadis, 2005), and possible many folds more for CTCs. All of these
pose signiﬁcant trauma in these cells and are likely to result on activa-
tion of the stress response and phenotypic changes. Second, the most
“dangerous” CTCs are those pre-programmed for migration and inva-
sion, the capillary beds provide the right environment for tissue pene-
tration, even when this process does not result in the seeding of
micrometastases. The latter would also result on substantial loss of
functionally signiﬁcant CTCs. Third, the low oxygen tension and nutrient
depravation in venous blood could affect CTCs, from compromising cell
viability to changing their phenotype. While the consequences of these
phenotypic changes are unclear, they could potentially affect the capac-
ity of many of the current methodologies to detect these cells. Future
studies owe to explore whether there are phenotypic differences
between CTCs isolated from venous and arterial blood.
Despite the mounting evidence supporting the use of arterial
blood, it is unlikely that this will be widely applied in clinical settings.
Arterial blood sample collection is usually more painful than regular ve-
nipuncture. Patients may experience moderate discomfort and longer
compression is required to prevent bleeding from the site. Although ar-
terial blood is routinely collected for determining arterial blood gases
and pH, it is a more dangerous procedure requiring in depth training
beyond the routine phlebotomist skills. Moreover, in studies requiring
sequential sampling, such as those for monitoring therapy response,
patient retention might be compromised if arterial blood collection is
implemented.
Nevertheless, the ﬁndings by Terai and colleagues that arterial blood
is a better source of CTCs than venous blood need to be consideredwhenthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1597E.S. Gray / EBioMedicine 2 (2015) 1596–1597planning projects involving CTCs. In particular, this will be important in
studies involving single cell analysis for genetic or phenotypic proﬁling,
where a reasonable number of CTCs per case need to be analyzed to pro-
vide relevant clinical information.
Disclosure
The author declares no conﬂicts of interest.
References
Aceto, N., Bardia, A., Miyamoto, D.T., Donaldson, M.C., Wittner, B.S., Spencer, J.A., Yu, M.,
Pely, A., Engstrom, A., Zhu, H., Brannigan, B.W., Kapur, R., Stott, S.L., Shioda, T.,
Ramaswamy, S., Ting, D.T., et al., 2014. Circulating tumor cell clusters are oligoclonal
precursors of breast cancer metastasis. Cell 158 (5), 1110–1122.
Alix-Panabieres, C., Pantel, K., 2014. Challenges in circulating tumour cell research. Nat.
Rev. Cancer 14 (9), 623–631.
Fang, Z.T., Zhang, W., Wang, G.Z., Zhou, B., Yang, G.W., Qu, X.D., Liu, R., Qian, S., Zhu, L., Liu,
L.X., Wang, J.H., 2014. Circulating tumor cells in the central and peripheral venous
compartment — assessing hematogenous dissemination after transarterial
chemoembolization of hepatocellular carcinoma. OncoTargets Ther. 7, 1311–1318.Jiao, L.R., Apostolopoulos, C., Jacob, J., Szydlo, R., Johnson, N., Tsim, N., Habib, N.A.,
Coombes, R.C., Stebbing, J., 2009. Unique localization of circulating tumor cells
in patients with hepatic metastases. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 27 (36),
6160–6165.
Maltoni, R., Fici, P., Amadori, D., Gallerani, G., Cocchi, C., Zoli, M., Rocca, A., Cecconetto, L.,
Folli, S., Scarpi, E., Serra, P., Fabbri, F., 2015. Circulating tumor cells in early breast
cancer: a connection with vascular invasion. Cancer Lett. 367 (1), 43–48.
Nedosekin, D.A., Juratli, M.A., Sarimollaoglu, M., Moore, C.L., Rusch, N.J., Smeltzer, M.S.,
Zharov, V.P., Galanzha, E.I., 2013. Photoacoustic and photothermal detection of circu-
lating tumor cells, bacteria and nanoparticles in cerebrospinal ﬂuid in vivo and
ex vivo. J. Biophotonics 6 (6–7), 523–533.
Papaioannou, T.G., Stefanadis, C., 2005. Vascular wall shear stress: basic principles and
methods. Hell. J. Cardiol. 46 (1), 9–15.
Rao, C.G., Chianese, D., Doyle, G.V., Miller, M.C., Russell, T., Sanders Jr., R.A., Terstappen,
L.W., 2005. Expression of epithelial cell adhesion molecule in carcinoma cells present
in blood and primary and metastatic tumors. Int. J. Oncol. 27 (1), 49–57.
Terai, M., Mu, Z., Eschelman, D., Gonsalves, C., Kageyama, K., Chervoneva, I., Orloff, M.,
Weight, R., Mastrangelo, M., Cristofanilli, M., Sato, T., 2015. Arterial blood, rather
than venous blood, is a better source for circulating melanoma cells. EBioMed. 2
(11), 1821–1826.
Warkiani, M.E., Wu, L., Tay, A.K., Han, J., 2015. Large-volume microﬂuidic cell sorting for
biomedical applications. Annu. Rev. Biomed. Eng.
